Hemagen Diagnostics Receivables

Hemagen Diagnostics (HMGN) currently reports a receivables of $590K as of September 2012. That compares with $620K in the prior-year period — down 4.5% year over year. Use the charts on this page to explore Hemagen Diagnostics's receivables history and peer comparisons.

Hemagen Diagnostics's receivables decreased from $620K to $590K — a 4.5% year-over-year decrease (period ending September 2012). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Hemagen Diagnostics reported $590K in receivables as of September 2012. That compares with $620K in the prior-year period — down 4.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $590K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Hemagen Diagnostics, and consider following HMGN for alerts when major investors trade the stock.

Hemagen Diagnostics is classified in the Healthcare sector. On receivables, it currently shows $590K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HMGN with unrelated industries.